Published on 22 May 2023 on Benzinga via Yahoo Finance
FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's (NASDAQ: ICPT) Ocaliva 25 mg, also known as Obeticholic acid (OCA), don't outweigh the risks in nonalcoholic steatohepatitis (NASH) patients with stage 2 or 3 fibrosis.
Insights from Jefferies Group (Trades, Portfolio)'s Latest 13F Filing for Q3 2023 Warning! GuruFo...
In this piece, we will take a look at the ten best performing healthcare ETFs in 2023. If you wan...
U.S. stocks traded lower this morning, with the Dow Jones falling around 150 points on Tuesday. F...
Intercept Pharmaceuticals ICPT incurred a loss of 14 cents per share (from continuing operations)...
Intercept Pharmaceuticals, Inc. ICPT announced a restructuring program in the wake of the recent ...
Intercept Pharmaceuticals, Inc. ICPT announced that the FDA issued a complete response letter (CR...
We feel now is a pretty good time to analyse Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) busi...
Canaccord Genuity has lowered the price target for Intercept Pharmaceutical Inc (NASDAQ: ICPT) fr...
Intercept Pharmaceuticals, Inc. ICPT announced that the FDA’s Gastrointestinal Drugs Advisory Com...
FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benef...
Copyright Statfolio @ 2025